MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
Francesco GigantiCaroline M MooreNicola L RobertsonNeil McCartanCharles JamesonSimon R J BottMathias WinklerGiulio GambarotaBrandon WhitcherRamiro CastroMark EmbertonClare AllenAlex KirkhamPublished in: European radiology (2017)
• Dutasteride increases ADC and reduces conspicuity in small mpMRI-visible prostate cancers. • Knowledge of dutasteride exposure is important in the interpretation of prostate mpMRI. • A lower threshold for triggering biopsy may be appropriate on dutasteride.
Keyphrases
- benign prostatic hyperplasia
- lower urinary tract symptoms
- clinical trial
- prostate cancer
- double blind
- placebo controlled
- diffusion weighted imaging
- contrast enhanced
- study protocol
- magnetic resonance imaging
- phase ii
- open label
- radical prostatectomy
- healthcare
- diffusion weighted
- phase iii
- randomized controlled trial
- young adults
- fine needle aspiration